Perimeter Medical Imaging AI Launches New Clinical Trial Site in Seattle, Washington

n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n

Vancouver –News Direct– Edge Medical Imaging AI

Adrian Mendes, CEO of Perimeter Medical Imaging, joined Proactive’s Steve Darling in announcing that the company has announced an additional clinical trial at the University of Washington at the Fred Hutch Cancer Center.

The Perimeter Institute clinical trial is a pivotal, multicenter, randomized, two-arm study comparing the generation of investigational B-series optical coherence tomography (OCT) scans from Perimeter. This generation is combined with Perimeter Institute’s proprietary ImgAssist AI software and is used in breast-conserving surgeries.

At the heart of this state-of-the-art technique is the use of complex, ultra-high-resolution, real-time imaging equipment to read about the removed tissue at the cellular level, providing data to surgeons.

Mendes emphasized the importance of this additional clinical trial site, as it plays a critical role in gathering valuable insights generated by the study. This knowledge will play a critical role in supporting the commercialization of Perimeter’s B-Series technology.

The company’s ultimate goal is to reshape cancer surgery by offering cutting-edge technology that not only improves patient outcomes but also helps reduce healthcare costs.

Proactive Investors

1 604-688-8158

na-editorial@proactiveinvestors. com

See the newsdirect. com edition: https://newsdirect. com/news/perimeter-medical-imaging-ai-initiates-new-clinical-trial-site-in-seattle-wa-543375171

Leave a Comment

Your email address will not be published. Required fields are marked *